Scios, Inc.

Scios, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
1981-01-01
Employees
509
Market Cap
-
Website

A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest

First Posted Date
2006-02-08
Last Posted Date
2011-06-10
Lead Sponsor
Scios, Inc.
Target Recruit Count
127
Registration Number
NCT00288730

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-12-26
Last Posted Date
2011-06-10
Lead Sponsor
Scios, Inc.
Target Recruit Count
255
Registration Number
NCT00270400

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

First Posted Date
2005-06-13
Last Posted Date
2013-11-07
Lead Sponsor
Scios, Inc.
Target Recruit Count
62
Registration Number
NCT00113893

Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

First Posted Date
2004-11-08
Last Posted Date
2010-10-22
Lead Sponsor
Scios, Inc.
Target Recruit Count
30
Registration Number
NCT00095680

A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure

Phase 2
Completed
Conditions
First Posted Date
2004-10-01
Last Posted Date
2011-05-20
Lead Sponsor
Scios, Inc.
Target Recruit Count
920
Registration Number
NCT00091520

SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate

Phase 2
Completed
Conditions
Interventions
First Posted Date
2004-08-20
Last Posted Date
2010-10-18
Lead Sponsor
Scios, Inc.
Target Recruit Count
302
Registration Number
NCT00089921
© Copyright 2024. All Rights Reserved by MedPath